Cantor Fitzgerald Has Weak Outlook for Amgen FY2025 Earnings
Research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Amgen in a research note issued to ...
FY2025 EPS Estimates for CVRx Reduced by Cantor Fitzgerald
Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for CVRx in a research report issued on Wednesday, ...
AST SpaceMobile, Inc. (ASTS): Cantor Fitzgerald Sees $30 Potential on AI and Defense Growth
We recently published a list of 9 Trending AI News Updates on Wall Street’s Radar. In this article, we are going to take a ...
Cantor Fitzgerald maintains NBIX overweight with $170 target
Cantor Fitzgerald reaffirmed its Overweight rating on Neurocrine Biosciences stock (NASDAQ:NBIX) with a consistent price target of $170.00. Currently trading at $150.51, the stock has shown strong ...
Cantor Fitzgerald begins coverage of five in ‘GovTech’ with three buys
As previously reported last night, Cantor Fitzgerald analyst Colin Canfield initiated coverage of five Government Technology & Space, or ...